针对糖尿病神经病变的基于植物成分的配方的隔离,表征,开发和评估
Rashmi Pathak1, Neetu Sachan2, Atul Kabra3
1Department of Pharmacy, Invertis University, Bareilly-243123, Uttar Pradesh, India.
概括
白色木提取物,特别是素,制成纳米乳液,显示出对大鼠糖尿病神经病变的保护作用. 这种天然化合物有助于恢复氧化途径,减少神经损伤.
科学领域:
- 药理学和传统医学的医学.
- 纳米技术在药物输送中的应用
- 神经科学和糖尿病研究研究
背景情况:
- 白树 (Morus alba) 以其潜在的治疗特性而闻名,特别是在治疗糖尿病和神经保护方面.
- 糖尿病神经病变是糖尿病的重要并发症,需要有效的治疗策略.
研究的目的:
- 从Morus alba中分离和描述一种植物成分,以便在治疗糖尿病神经病变时使用.
- 开发和评估分离植物成分的纳米乳液配方,以提高输送和疗效.
- 在糖尿病神经病变的动物模型中评估纳米乳液配方的安全性和治疗效果.
主要方法:
- 使用列色谱和通过质谱,FTIR和NMR进行表征的植物化学隔离.
- 基于素的纳米乳液的开发和表征,包括物理和化学稳定性测试.
- 评估急性口服毒性和针对老鼠的阿洛克桑诱导糖尿病神经病变的疗效,包括行为,血液学,组织病理学和生物标志物分析.
主要成果:
- 隔离的植物成分被确定为chrysin.
- 开发的纳米乳液配方是稳定的,并满足了所有表征参数.
- 素纳米乳液在老鼠中显示出对糖尿病神经病变的显著保护作用,没有观察到毒性.
- 生物标志物分析表明氧化途径的恢复,这表明了关键的作用机制.
结论:
- 从Morus alba中分离出来的植物成分素,当制成纳米乳液时,对糖尿病神经病变具有显著的保护和有益作用.
- 纳米乳液配方是安全有效的,主要是通过减少氧化损伤和恢复氧化途径在阿洛诱导的糖尿病神经病变模型.
更多相关视频
09:39Establishing a Mouse Model of a Pure Small Fiber Neuropathy with the Ultrapotent Agonist of Transient Receptor Potential Vanilloid Type 1
Published on: February 13, 2018
9.6K
08:20Systematic Approach to Identify Novel Antimicrobial and Antibiofilm Molecules from Plants' Extracts and Fractions to Prevent Dental Caries
Published on: March 31, 2021
6.4K
相关概念视频
Diabetes: Management and Pharmacotherapy
319
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
319
Insulin Formulations: Types and Delivery
232
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
232
